谷歌浏览器插件
订阅小程序
在清言上使用

Clinicopathological Characterization of Next-Generation Sequencing Detected Mutations in Lung Cancers—a Single-Center Experience

Translational lung cancer research(2024)

引用 0|浏览17
暂无评分
摘要
Background: Despite many advances in molecular procedures many lung cancer patients do not receive full panel testing. This can limit the comprehensive understanding of their disease and potentially hinder personalized treatment options. Methods: In this retrospective analysis, we used results from next -generation sequencing (NGS) testing of 154 patients with adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the lung treated at the University Hospital, Ludwig-Maximilians Universit & auml;t (LMU) Munich between 2018 and 2021. We compared different clinicopathological features and patients' baseline characteristics with results of NGS testing. We used t -test and analysis of variance (ANOVA) to compare metric- and x 2 -test and Fisher's exact test to compare categorical variables. Results: NGS testing found mutations in 107 (69.5%) patients; 44 patients (28.6%) had more than one mutation. The majority (79.2%) of patients had AC and 64.9% were metastasized at diagnosis. Patients with detected mutations had significantly higher PD -L1 expression than those without mutations (36.4% vs. 19.2%, P=0.005). Mean PD -L1 expression also differed between different mutations ranging from 24.0% in EGFR to 56.8% in patients with MET alterations, and increased with the number of different mutations (P=0.07). EGFR mutations were significantly more common in females compared to males (22.9% vs. 9.5%, P=0.04) and PIK3CA mutations significantly more common in SCC (21.9% vs. 2.5%, P=0.004). We found 23 different mutations in AC and 13 different gene mutations in SCC. Conclusions: Mutation profiles differed by histological type and metastases status and were significantly associated with PD -L1 expression. In the context of limited resources, our results may help prioritize patient for testing when tissue material and funding is limited.
更多
查看译文
关键词
Non-small cell lung cancer (NSCLC),driver mutations,next-generation sequencing (NGS),tyrosine kinase inhibitor (TKI)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要